Varlilumab (INN;[1] development code CDX-1127) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies.
[2] It is an anti-CD27 antibody and helps activate T-cells.
It (in combination with ONT-10) has undergone a phase 1B clinical trial for advanced breast or ovarian cancer.
[4] In combination with anti-PD-1 nivolumab it has undergone a phase 1/2 trial for advanced refractory solid tumours[5] This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.Immune activation: Dostarlimab Other: Ibalizumab